Astellas Pharma News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

23.03.23	Pfizer And Astellas Say Phase 3 EMBARK Study Of XTANDI To Treat Prostate Cancer Meets Primary Goal (RTTNews)
21.03.23	Astellas Announces Positive Findings from Phase 3 GLOW Trial of Zolbetuximab during March ASCO Plenary Series (PR Newswire)
17.03.23	Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer (PR Newswire)
14.03.23	Astellas : Phase 3 Study Of Xtandi In Metastatic Hormone-sensitive Prostate Cancer Meets Main Goal (RTTNews)
14.03.23	Results from Astellas' Pivotal Phase 3 SKYLIGHT 1™ Study of Fezolinetant for Vasomotor Symptoms Due to Menopause Published in The Lancet (PR Newswire)
14.03.23	Astellas Announces Phase 3 China ARCHES Study of XTANDI® Meets Primary Endpoint (PR Newswire)
10.03.23	Astellas and Seagen Announce China's National Medical Products Administration Accepts Biologics License Application for Enfortumab Vedotin in Certain Patients with Locally Advanced or Metastatic U... (PR Newswire)
09.03.23	Astellas and BMT CTN Announce Topline Results from Phase 3 MORPHO Trial of Gilteritinib (PR Newswire)
22.02.23	Astellas Announces Update on Preliminary Safety and Efficacy Data from FORTIS Study of Investigational AT845 in Adults with Late-Onset Pompe Disease (PR Newswire)
20.02.23	Astellas Provides Update on Fezolinetant New Drug Application in U.S. (PR Newswire)
09.02.23	Astellas Commits to Achieve Net Zero Greenhouse Gas Emissions by 2050 (PR Newswire)
06.02.23	Astellas Pharma Board Approves Changes Of Management Structure (RTTNews)
06.02.23	Astellas Announces Change of President and CEO and Management Structure (PR Newswire)
24.01.23	Sandoz To Acquire Antifungal Agent Mycamine From Astellas Pharma (RTTNews)
24.01.23	Astellas Transfers MYCAMINE® Product Worldwide (PR Newswire)
20.01.23	Astellas Pharma : FDA Lifts Clinical Hold On Trial Of AT845 In Late-Onset Pompe Disease (RTTNews)
20.01.23	Astellas Announces Hold Lifted by FDA on FORTIS Clinical Trial of AT845 Investigational Treatment for Adult Patients with Late-Onset Pompe Disease (PR Newswire)
19.01.23	Astellas to Present Positive Findings from Phase 3 SPOTLIGHT Trial of Zolbetuximab during 2023 ASCO GI Cancers Symposium (PR Newswire)
19.01.23	Astellas Receives SBTi Approval for Revised Science-Based Climate Goals to Reduce Greenhouse Gas Emissions (PR Newswire)
09.01.23	Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease (PR Newswire)
22.12.22	Astellas, 3 Other Companies Collaborate To Reduce Environmental Burden In Field Of Pharma Packaging (RTTNews)
22.12.22	Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging (PR Newswire)
20.12.22	Astellas: PADCEV, KEYTRUDA Granted Priority Review In Treatment Of Metastatic Urothelial Cancer (RTTNews)
20.12.22	Astellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment ... (PR Newswire)
16.12.22	Astellas Announces Positive Results From Phase 3 Trial Of Zolbetuximab Combination In Gastric Cancer (RTTNews)
16.12.22	Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 GLOW Trial as First-Line Treatment in Claudin 18.2 Positive, HER2-negative Locally Advanced Unresectable or Metastatic Gastric and... (PR Newswire)
14.12.22	Astellas and MBC BioLabs Announce 2022 Future Innovator Prize Awarded to Bespoke Biotherapeutics and Cellinfinity Bio (PR Newswire)
17.11.22	Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 SPOTLIGHT Trial as First-Line Treatment in Claudin 18.2 Positive, HER2-Negative Locally Advanced or Metastatic Gastric and Gastroe... (PR Newswire)
25.10.22	Astellas Pharma To Support Development Of Taysha's AAV-based Gene Therapy Programs (RTTNews)
25.10.22	Astellas and Taysha Gene Therapies Announce Strategic Investment to Support Development of Taysha's AAV-based Gene Therapy Programs (PR Newswire)
12.10.22	Astellas to Present Findings from Phase 3 Long-Term Safety Study of Fezolinetant in Oral Session at The North American Menopause Society 2022 Annual Meeting (PR Newswire)
04.10.22	Astellas and Pantherna Enter into a New Technology Evaluation Agreement for Research with Expanded Target Organ to Generate mRNA-Based Regenerative Medicine Programs Using Direct Reprogramming (PR Newswire)
30.09.22	Astellas : EMA Accepts Marketing Authorization Application For Fezolinetant (RTTNews)
30.09.22	European Medicines Agency Accepts Astellas' Marketing Authorization Application for Fezolinetant (PR Newswire)
20.09.22	Astellas and MBC BioLabs Announce Astellas Future Innovator Prize to Help Biotech Start-ups Accelerate Early Drug Discovery and Research Efforts (PR Newswire)
12.09.22	Seagen, Astellas, Merck: EV-103 Results Support Investigation Of Enfortumab Vedotin, Pembrolizumab (RTTNews)
12.09.22	Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothe... (PR Newswire)
05.09.22	Astellas Announces Topline Results from Phase 3 Long-Term Safety Study of Fezolinetant in Mainland China (PR Newswire)
18.08.22	U.S. FDA Accepts Astellas' New Drug Application for Fezolinetant (PR Newswire)
02.08.22	Astellas Announces Management Structure (PR Newswire)
26.07.22	Astellas, Seagen Report Positive Topline Results For Padcev With Keytruda To Treat Urothelial Cancer (RTTNews)
26.07.22	Astellas and Seagen Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer (PR Newswire)
22.07.22	Astellas Unveils Plans to Open New Biotech Campus in South San Francisco (PR Newswire)
05.07.22	Mogrify, Astellas Pharma Announce Research Agreement (RTTNews)
05.07.22	Mogrify and Astellas announce collaboration to conduct research on in vivo regenerative medicine approaches to address sensorineural hearing loss (PR Newswire)
28.06.22	Astellas, Sutro Collaborate To Advance Novel Immunostimulatory Antibody-Drug Conjugates (RTTNews)
28.06.22	Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs) (PR Newswire)
27.06.22	FDA Places Clinical Hold On Astellas' Phase 1/2 Trial Of AT845 In Late-Onset Pompe Disease (RTTNews)
27.06.22	Astellas Announces FDA Update on the FORTIS Clinical Trial of AT845 in Adults with Late-Onset Pompe Disease (PR Newswire)
24.06.22	Astellas Pharma Submits Fezolinetant NDA To FDA (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Astellas Pharma Inc Unsponsored American Deposit Receipt Repr 1-4 Sh

Aktien Top/Flop

Meistgelesene Nachrichten